BioStock: Elicera on the positive clinical effect in cancer trial

Elicera Therapeutics recently participated at the Oncolytic Virotherapy Summit in Boston, where the immuno-oncology company presented positive data regarding ELC-100. Clinical activity in the form of a reduction in metastases has now been observed in two of the eight patients evaluated so far, providing some support for the candidate’s potential in neuroendocrine tumours (NET). BioStock spoke with Elicera’s Co-founder Di Yu to learn more about the recently announced results.

Read the full interview with Elicera’s Co-founder Di Yu at biostock.se:

https://www.biostock.se/en/2022/12/elicera-on-the-positive-clinical-effect-in-cancer-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/